Quotes.ino.com needs to review the security of your connection before proceeding. The compound annual growth rate measures an investment’s annual growth rate over Forex news a period of time, assuming profits are reinvested at the end of each year. IBD Videos Get market updates, educational videos, webinars, and stock analysis.
- Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases.
- It is focused on discovering, developing and delivering therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.
- The Barchart Technical Opinion widget shows you today’s overally Barchart Opinion with general information on how to interpret the short and longer term signals.
- Upon request, the advisor will provide a list of all recommendations made during the past twelve months.
- If a user or application submits more than 10 requests per second, further requests from the IP address may be limited for a brief period.
An analysis of the technical chart of Biogen Inc. shows the stock could be set to rebound by about 7%, giving shares the chance to rise back towards $282 from its price of roughly $263, a jump of about 7.5%. Biogen shares were up by roughly 1% on April 24, after dotbig the company reported better than expected first-quarter earnings per share, and revenue that was in line with estimates. Biogen and Idec merged in 2003, combining forces to market Biogen’s multiple sclerosis drug Avonex and Idec’s cancer drug Rituxan.
Recently Viewed Tickers
Gurus may be added or dropped from the GuruFocus site at any time. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily. Biogen, Inc. is dotbig a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis.
Following the earnings report the stock price went down -0.386%. The company reported $4.77 earnings per share for the quarter, beating the consensus estimate of $4.126 by $0.644. Biogen scarcity Forex value goes up after Roche miss in Alzheimer’s, says Jefferies After Roche reported negative Phase 3 topline data for gantenerumab in Alzheimer’s disease, Jefferies analyst Michael Yee…
Analyst Ratings
Robert Francis, former CEO of Sandoz and an executive at Novartis AG and former executive at Biogen Inc. , will beco… If a user or application submits more than 10 requests per second, further requests from the IP address may be limited for a brief period. Once the rate of requests has dropped below the threshold https://www.plus500.com/en-US/Trading/Forex for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website. By using this site, you are agreeing to security monitoring and auditing.
72.0% of employees surveyed would recommend working at Biogen to a friend. 27 https://dotbig.com/ people have added Biogen to their MarketBeat watchlist in the last 30 days.
Key Data
A triple bottom is a bullish chart pattern used in technical analysis that is characterized by three equal lows followed by a breakout above resistance. A pullback refers to the falling https://dotbig.com/markets/stocks/BIIB/ back of a price of a stock or commodity from its recent pricing peak. The offers that appear in this table are from partnerships from which Investopedia receives compensation.
Introducing MarketDiem by IBD!
We are continuously working to improve our web experience, and encourage users to Contact Us for feedback and https://dotbig.com/markets/stocks/BIIB/ accommodation requests. Join thousands of traders who make more informed decisions with our premium features.
Biogen Lifts Profit Estimates as Investors Look to Alzheimer’s Drug
You can read more about the power of momentum in assessing share price movements on Stockopedia. Biogen’s BIIB, +4.96% stock is rising again as investors double down on the company’s promising yet still experimental treatment for Alzheimer’s disease. Even though many stocks have fallen sharply in price, not BIIB stock price all are bargains — investors must remains selective. To see a complete breakdown of any of the ETFs included in the table below, including sector, market cap, and country allocations, click on the ticker symbol. Biogen reported an EPS of $4.77 in its last earnings report, beating expectations of $4.126.
Billionaire investor and hedge fund manager Steve Cohen’s Point 72 Asset Management has disclosed some interesting stakes in… 394 employees have rated Biogen Inc stock price Biogen Chief Executive Officer Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among the company’s employees.
Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Results BIIB stock price today are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating.
The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm , Spinraza (spinal muscular atrophy ) and Aduhelm (Alzheimer’s disease). Incorporated in 1978, Massachusetts-based Biogen, Inc. is a biopharmaceutical company, which discovers, develops, and delivers therapies for the treatment https://dotbig.com/ of neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of seve… Intraday Data provided by FACTSET and subject to terms of use.
